ScholarLens Back to search
2004•Unpublished venueRequires access

Triptans for Migraine

Jie Jack Li, Douglas S. Johnson, Drago R. Sliskovic, Bruce D. Roth

Open publisher page 5 citations

Abstract

Sumatriptan (Imitrex®) is a selective 5-HT1B/1D agonist and was the first specific antimigraine medication. Since the introduction of sumatriptan, several second-generation triptans have entered the marketplace, including zolmitriptan (Zomig®), naratriptan (Amerge®), rizatriptan (Maxalt®), almotriptan (Axert®), frovatriptan (Frova®) and eletriptan (Relpax®). Their pharmacology and pharmacokinetics are presented briefly in the background section. The subsequent sections describe in detail the various syntheses of sumatriptan, zolmitriptan, naratriptan, rizatriptan, almotriptan, frovatriptan and eletriptan.

About this research paper

What this paper is about

Sumatriptan (Imitrex®) is a selective 5-HT1B/1D agonist and was the first specific antimigraine medication. Since the introduction of sumatriptan, several second-generation triptans have entered the marketplace, including zolmitriptan (Zomig®), naratriptan (Amerge®), rizatriptan (Maxalt®), almotriptan (Axert®), frovatriptan (Frova®) and eletriptan (Relpax®). Their pharmacology and pharmacokinetics are presented briefly in the background section. The subsequent sections describe in detail the various syntheses of sumatriptan, zolmitriptan, naratriptan, rizatriptan, almotriptan, frovatriptan and eletriptan.

Why it matters

OpenAlex reports 5 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Sumatriptan (Imitrex®) is a selective 5-HT1B/1D agonist and was the first specific antimigraine medication. Since the introduction of sumatriptan, several second-generation triptans have entered the marketplace, including zolmitriptan (Zomig®), naratriptan (Amerge®), rizatriptan (Maxalt®), almotriptan (Axert®), frovatriptan (Frova®) and eletriptan (Relpax®). Their pharmacology and pharmacokinetics are presented briefly in the background section. The subsequent sections describe in detail the various syntheses of sumatriptan, zolmitriptan, naratriptan, rizatriptan, almotriptan, frovatriptan and eletriptan.

Key concepts: Rizatriptan, Zolmitriptan, Sumatriptan, Triptans, Medicine, Tryptamines, Migraine, Pharmacology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Triptans for Migraine — Research Paper | ScholarLens